ASTRAZENECA PHARMA INDIA
|
ASTRAZENECA PHARMA INDIA Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 |
| CEPS(Rs) | 62.29 | 70.58 | 46.22 | 31.42 | 45.37 |
| DPS(Rs) | 32.00 | 24.00 | 16.00 | 10.00 | 2.00 |
| Book NAV/Share(Rs) | 305.28 | 283.45 | 234.45 | 203.78 | 181.83 |
| Tax Rate(%) | 25.98 | 26.43 | 25.96 | 25.82 | 26.59 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.74 | 14.17 | 16.39 | 10.65 | 16.58 |
| EBIT Margin(%) | 9.16 | 16.95 | 13.37 | 10.38 | 15.69 |
| Pre Tax Margin(%) | 9.08 | 16.86 | 13.31 | 10.26 | 15.56 |
| PAT Margin (%) | 6.72 | 12.40 | 9.85 | 7.61 | 11.42 |
| Cash Profit Margin (%) | 9.04 | 13.55 | 11.47 | 9.70 | 13.88 |
| Performance Ratios | |||||
| ROA(%) | 7.43 | 13.35 | 9.37 | 6.65 | 11.31 |
| ROE(%) | 15.73 | 24.95 | 18.13 | 12.78 | 22.83 |
| ROCE(%) | 21.29 | 33.94 | 24.49 | 17.36 | 31.24 |
| Asset Turnover(x) | 1.11 | 1.08 | 0.95 | 0.87 | 0.99 |
| Sales/Fixed Asset(x) | 8.51 | 7.11 | 5.79 | 4.93 | 5.58 |
| Working Capital/Sales(x) | 2.69 | 2.26 | 2.23 | 2.17 | 2.59 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.12 | 0.14 | 0.17 | 0.20 | 0.18 |
| Receivable days | 35.81 | 36.53 | 35.03 | 38.57 | 37.62 |
| Inventory Days | 82.25 | 58.60 | 59.85 | 67.64 | 72.59 |
| Payable days | 124.39 | 131.27 | 214.92 | 220.48 | 246.52 |
| Valuation Parameters | |||||
| PER(x) | 185.90 | 82.35 | 81.76 | 103.71 | 80.66 |
| PCE(x) | 138.16 | 75.38 | 70.26 | 81.33 | 66.34 |
| Price/Book(x) | 28.19 | 18.77 | 13.85 | 12.54 | 16.55 |
| Yield(%) | 0.37 | 0.45 | 0.49 | 0.39 | 0.07 |
| EV/Net Sales(x) | 12.22 | 9.88 | 7.60 | 7.37 | 8.82 |
| EV/Core EBITDA(x) | 71.21 | 58.36 | 39.84 | 58.85 | 48.37 |
| EV/EBIT(x) | 132.93 | 57.96 | 56.54 | 70.72 | 55.96 |
| EV/CE(x) | 27.23 | 17.97 | 12.94 | 11.62 | 8.21 |
| M Cap / Sales | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 32.48 | 29.17 | 24.50 | -0.98 | -2.19 |
| Core EBITDA Growth(%) | 34.37 | 14.66 | 89.44 | -31.94 | 10.94 |
| EBIT Growth(%) | -28.50 | 63.84 | 60.41 | -34.47 | 11.35 |
| PAT Growth(%) | -28.34 | 62.66 | 61.19 | -33.98 | 29.21 |
| EPS Growth(%) | -28.34 | 62.66 | 61.19 | -33.98 | 29.21 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 1.70 | 2.23 | 1.93 | 1.95 | 1.84 |
| Quick Ratio(x) | 1.10 | 1.74 | 1.54 | 1.59 | 1.42 |
| Interest Cover(x) | 108.10 | 183.95 | 213.86 | 88.41 | 117.60 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of ASTRAZENECA PHARMA INDIA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ASTRAZENECA PHARMA INDIA | ₹22,955.8 Cr | 4% | 1.8% | 32.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹409,219.0 Cr | 0.4% | 1.7% | 2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,227.0 Cr | -0.3% | -3.8% | 35.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹126,643.0 Cr | 3.9% | 11.8% | 20% | Stock Analytics | |
| CIPLA | ₹125,541.0 Cr | 1.5% | 3.8% | 2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,063.0 Cr | -0.5% | -0.1% | -5.1% | Stock Analytics | |
ASTRAZENECA PHARMA INDIA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ASTRAZENECA PHARMA INDIA | 4% |
1.8% |
32.9% |
| SENSEX | -1.2% |
-3% |
-0.2% |
You may also like the below Video Courses
